Symbiotec Pharmalab
Latest news, explainers and analysis on Symbiotec Pharmalab. Tracking 2 stories on Arth Vani.
Connected in the graph
Latest on Symbiotec Pharmalab
IPOBreakingIndian Primary Market Heats Up: 10 IPOs to Raise Over ₹3,500 Crore This Week
The Indian stock market is set for a busy week with 10 initial public offerings (IPOs) hitting the primary market to raise over ₹3,500 crore. The lineup includes six mainboard issues and four SME offerings, led by the significant Symbiotec Pharmalab IPO.
IPOBreakingSymbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion
Symbiotec Pharmalab, a global leader in corticosteroid and steroidal-hormone APIs, is planning an Initial Public Offering (IPO) to raise ₹150 crore. The funds are earmarked for repaying existing debt and expanding its operational capabilities. The company has shown consistent revenue and EBITDA growth, primarily driven by its international market presence, particularly in Europe.
IPO investments are subject to market risk and allotment. Read the RHP / prospectus before applying; grey-market premium (GMP) is unofficial and unreliable. Some listings may be sponsored. Not investment advice.